Symbols / PPBT
PPBT Chart
About
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.25M |
| Enterprise Value | 450.74M | Income | -3.25M | Sales | — |
| Book/sh | 0.04 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 9 | IPO | — |
| P/E | — | Forward P/E | -0.26 | PEG | — |
| P/S | — | P/B | 14.05 | P/C | — |
| EV/EBITDA | -90.31 | EV/Sales | — | Quick Ratio | 1.73 |
| Current Ratio | 1.78 | Debt/Eq | 0.78 | LT Debt/Eq | — |
| EPS (ttm) | -46.10 | EPS next Y | -1.93 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 08:00 | ROA | -8.48% |
| ROE | -10.48% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 9.03M |
| Shs Float | 848.52M | Short Float | 1.40% | Short Ratio | 1.23 |
| Short Interest | — | 52W High | 3.15 | 52W Low | 0.46 |
| Beta | -0.72 | Avg Volume | 328.99K | Volume | 41.00K |
| Target Price | $34.00 | Recom | None | Prev Close | $0.54 |
| Price | $0.51 | Change | -5.97% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$34.00
Mean price target
2. Current target
$0.51
Latest analyst target
3. DCF / Fair value
$-3.47
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.51
Low
$34.00
High
$34.00
Mean
$34.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $33 |
| 2024-09-20 | main | HC Wainwright & Co. | Buy → Buy | $33 |
| 2024-08-19 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-07-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-21 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-26 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-03-07 | main | Chardan Capital | Buy → Buy | $11 |
| 2024-03-05 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-02-27 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-11-21 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-08-31 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-08-30 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-07-21 | init | JonesTrading | — → Buy | $8 |
| 2023-05-17 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-05-17 | reit | Chardan Capital | Buy → Buy | $11 |
| 2023-02-09 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2023-02-09 | reit | Chardan Capital | — → Buy | $11 |
| 2022-10-17 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2022-09-08 | init | Chardan Capital | — → Buy | $11 |
- Purple Biotech (NASDAQ: PPBT) unveils CAPTN-3 data on tumor regression and PD-1–resistant models - Stock Titan hu, 11 Dec 2025 08
- Purple Biotech stock soars after manufacturing milestone for tri-specific antibody - Investing.com Wed, 29 Oct 2025 07
- Why Is Purple Biotech Stock (PPBT) Up 95% Today? - TipRanks Wed, 29 Oct 2025 07
- Purple Biotech Ltd. (PPBT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Wed, 29 Oct 2025 14
- Purple Biotech Announces Pricing of Up To $18 Million Public Off - GuruFocus hu, 04 Sep 2025 07
- Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification - GlobeNewswire Mon, 20 Oct 2025 07
- Purple Biotech Shares Soar 92% On Breakthrough For Experimental Cancer Drug - Stocktwits Wed, 29 Oct 2025 07
- Purple Biotech Announces Pricing of Up To $18 Million Public Offering - Yahoo Finance hu, 04 Sep 2025 07
- Experimental cancer antibody stays safer even at 300x dose - Stock Titan Wed, 07 Jan 2026 08
- Purple Biotech’s Impressive Leap: What’s Driving It? - StocksToTrade Wed, 29 Oct 2025 07
- Purple Biotech Announces Extraordinary General Meeting for December 2025 - TipRanks ue, 28 Oct 2025 20
- Purple Biotech Ltd. Advances CAPTN-3 Platform with Development of Second Tri-Specific Antibody and Reports Financial Results for Q3 2025 - Quiver Quantitative Fri, 14 Nov 2025 08
- Purple Biotech Reaches Manufacturing Milestone for IM1240 Antibody - TipRanks Wed, 29 Oct 2025 07
- H.C. Wainwright lifts Purple Biotech stock target to $34 - Investing.com Fri, 30 May 2025 07
- 26,000 Human Transcriptomes: Purple Biotech's Novel Cancer Drug Shows Promise in Resistant Tumors - Stock Titan hu, 04 Sep 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -10.79M | -23.73M | -21.80M | -17.38M |
| TotalUnusualItems | 3.74M | 4.00M | 307.00K | -133.00K |
| TotalUnusualItemsExcludingGoodwill | 3.74M | 4.00M | 307.00K | -133.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.24M | -19.88M | -21.67M | -17.74M |
| ReconciledDepreciation | 186.00K | 197.00K | 201.00K | 231.00K |
| EBITDA | -7.05M | -19.72M | -21.49M | -17.52M |
| EBIT | -7.24M | -19.92M | -21.69M | -17.75M |
| NetInterestIncome | -212.00K | -1.71M | 536.00K | 241.00K |
| InterestExpense | 41.00K | 56.00K | 67.00K | 79.00K |
| InterestIncome | 260.00K | 474.00K | 532.00K | 320.00K |
| NormalizedIncome | -10.98M | -23.88M | -21.98M | -17.61M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.24M | -19.88M | -21.67M | -18.38M |
| TotalExpenses | 10.80M | 22.27M | 22.60M | 17.93M |
| TotalOperatingIncomeAsReported | -11.01M | -22.27M | -22.60M | -17.93M |
| DilutedAverageShares | 1.64M | 1.11M | 904.05K | 878.40K |
| BasicAverageShares | 1.64M | 1.11M | 904.05K | 878.40K |
| DilutedEPS | -4.44 | -17.96 | -24.00 | -21.00 |
| BasicEPS | -4.44 | -17.96 | -24.00 | -21.00 |
| DilutedNIAvailtoComStockholders | -7.24M | -19.88M | -21.67M | -18.38M |
| NetIncomeCommonStockholders | -7.24M | -19.88M | -21.67M | -18.38M |
| NetIncome | -7.24M | -19.88M | -21.67M | -18.38M |
| MinorityInterests | 39.00K | 97.00K | 92.00K | 84.00K |
| NetIncomeIncludingNoncontrollingInterests | -7.28M | -19.98M | -21.76M | -18.47M |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | -642.00K | |
| NetIncomeContinuousOperations | -7.28M | -19.98M | -21.76M | -17.83M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -7.28M | -19.98M | -21.76M | -17.83M |
| OtherIncomeExpense | 3.74M | 4.00M | 307.00K | -133.00K |
| SpecialIncomeCharges | -202.00K | 0.00 | 0.00 | |
| WriteOff | 202.00K | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | 3.94M | 4.00M | 307.00K | -133.00K |
| NetNonOperatingInterestIncomeExpense | -212.00K | -1.71M | 536.00K | 241.00K |
| TotalOtherFinanceCost | 431.00K | 2.12M | -71.00K | |
| InterestExpenseNonOperating | 41.00K | 56.00K | 67.00K | 79.00K |
| InterestIncomeNonOperating | 260.00K | 474.00K | 532.00K | 320.00K |
| OperatingIncome | -10.80M | -22.27M | -22.60M | -17.93M |
| OperatingExpense | 10.80M | 22.27M | 22.60M | 17.93M |
| OtherOperatingExpenses | 62.00K | 196.00K | 120.00K | 55.00K |
| DepreciationAmortizationDepletionIncomeStatement | 186.00K | 197.00K | 201.00K | 231.00K |
| DepreciationAndAmortizationInIncomeStatement | 186.00K | 197.00K | 201.00K | 231.00K |
| DepreciationIncomeStatement | 186.00K | 197.00K | 201.00K | 231.00K |
| ResearchAndDevelopment | 7.62M | 17.03M | 16.32M | 11.83M |
| SellingGeneralAndAdministration | 2.94M | 4.84M | 5.96M | 5.82M |
| GeneralAndAdministrativeExpense | 2.94M | 4.84M | 5.96M | 5.82M |
| OtherGandA | 918.00K | 1.15M | 1.32M | 1.50M |
| SalariesAndWages | 2.02M | 3.69M | 4.64M | 4.32M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 1.00 | 1.00 | 1.00 | |
| OrdinarySharesNumber | 517.13M | 252.38M | 184.82M | 178.00M |
| ShareIssued | 517.13M | 252.38M | 184.82M | 178.00M |
| TotalDebt | 183.00K | 351.00K | 515.00K | 749.00K |
| TangibleBookValue | 5.02M | 6.16M | 26.23M | 44.34M |
| InvestedCapital | 32.86M | 34.21M | 46.91M | 64.83M |
| WorkingCapital | 4.92M | 6.09M | 26.20M | 44.22M |
| NetTangibleAssets | 5.02M | 6.16M | 26.23M | 44.34M |
| CapitalLeaseObligations | 183.00K | 351.00K | 515.00K | 749.00K |
| CommonStockEquity | 32.86M | 34.21M | 46.91M | 64.83M |
| TotalCapitalization | 32.86M | 34.21M | 46.91M | 64.83M |
| TotalEquityGrossMinorityInterest | 32.91M | 34.30M | 47.10M | 65.11M |
| MinorityInterest | 51.00K | 90.00K | 187.00K | 279.00K |
| StockholdersEquity | 32.86M | 34.21M | 46.91M | 64.83M |
| OtherEquityInterest | 30.02M | 38.55M | 38.18M | 36.88M |
| GainsLossesNotAffectingRetainedEarnings | -98.00K | -79.00K | -104.00K | -98.00K |
| OtherEquityAdjustments | -98.00K | -79.00K | -104.00K | -98.00K |
| RetainedEarnings | -144.69M | -137.45M | -117.57M | -95.91M |
| AdditionalPaidInCapital | 147.63M | 133.18M | 126.41M | 123.95M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 4.13M | 10.01M | 7.52M | 5.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 140.00K | 304.00K | 466.00K | 842.00K |
| DerivativeProductLiabilities | 2.52M | 0.00 | ||
| EmployeeBenefits | 140.00K | 141.00K | 145.00K | 292.00K |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 140.00K | 141.00K | 145.00K | 292.00K |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 163.00K | 321.00K | 550.00K |
| LongTermCapitalLeaseObligation | 0.00 | 163.00K | 321.00K | 550.00K |
| CurrentLiabilities | 3.99M | 9.70M | 7.06M | 4.25M |
| OtherCurrentLiabilities | 1.15M | 2.52M | ||
| CurrentDebtAndCapitalLeaseObligation | 183.00K | 188.00K | 194.00K | 199.00K |
| CurrentCapitalLeaseObligation | 183.00K | 188.00K | 194.00K | 199.00K |
| PayablesAndAccruedExpenses | 2.65M | 7.00M | 6.86M | 4.05M |
| CurrentAccruedExpenses | 818.00K | 2.79M | 4.03M | 1.97M |
| Payables | 1.84M | 4.21M | 2.83M | 2.08M |
| OtherPayable | 65.00K | 53.00K | 91.00K | 84.00K |
| DuetoRelatedPartiesCurrent | 317.00K | 620.00K | 607.00K | 527.00K |
| AccountsPayable | 1.46M | 3.53M | 2.13M | 1.47M |
| TotalAssets | 37.04M | 44.30M | 54.62M | 70.20M |
| TotalNonCurrentAssets | 28.13M | 28.51M | 21.37M | 21.73M |
| NonCurrentPrepaidAssets | 0.00 | 160.00K | ||
| InvestmentsAndAdvances | 0.00 | 187.00K | ||
| OtherInvestments | 0.00 | 187.00K | ||
| GoodwillAndOtherIntangibleAssets | 27.84M | 28.04M | 20.68M | 20.48M |
| OtherIntangibleAssets | 27.84M | 28.04M | ||
| NetPPE | 288.00K | 470.00K | 682.00K | 896.00K |
| GrossPPE | 288.00K | 470.00K | 682.00K | 896.00K |
| OtherProperties | 124.00K | 154.00K | 215.00K | 277.00K |
| BuildingsAndImprovements | 164.00K | 316.00K | 467.00K | 619.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.91M | 15.79M | 33.26M | 48.47M |
| OtherCurrentAssets | 109.00K | 171.00K | 146.00K | 268.00K |
| PrepaidAssets | 205.00K | 997.00K | 1.00M | |
| Receivables | 275.00K | 205.00K | 997.00K | 1.00M |
| OtherReceivables | 275.00K | 205.00K | 997.00K | 1.00M |
| CashCashEquivalentsAndShortTermInvestments | 8.52M | 15.41M | 32.11M | 47.20M |
| OtherShortTermInvestments | 1.12M | 923.00K | 17.08M | 36.31M |
| CashAndCashEquivalents | 7.40M | 14.49M | 15.03M | 10.89M |
| CashFinancial | 14.49M | 15.03M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -14.37M | -19.93M | -16.96M | -15.37M |
| RepaymentOfDebt | -183.00K | -168.00K | -165.00K | -153.00K |
| IssuanceOfCapitalStock | 5.81M | 1.56M | 1.50M | 564.00K |
| CapitalExpenditure | -3.00K | -228.00K | -115.00K | |
| EndCashPosition | 7.40M | 14.49M | 15.03M | 10.89M |
| BeginningCashPosition | 14.49M | 15.03M | 10.89M | 11.25M |
| EffectOfExchangeRateChanges | -4.00K | 54.00K | -153.00K | -24.00K |
| ChangesInCash | -7.08M | -595.00K | 4.29M | -333.00K |
| CashFlowFromDiscontinuedOperation | -374.00K | |||
| FinancingCashFlow | 6.77M | 5.45M | 1.11M | 1.51M |
| CashFromDiscontinuedFinancingActivities | 0.00 | 0.00 | ||
| CashFlowFromContinuingFinancingActivities | 6.77M | 5.45M | 1.11M | 1.51M |
| NetOtherFinancingCharges | -836.00K | -890.00K | -152.00K | -24.00K |
| InterestPaidCFF | -44.00K | -56.00K | -67.00K | -75.00K |
| ProceedsFromStockOptionExercised | 2.03M | 5.00M | 0.00 | 1.20M |
| CashDividendsPaid | 0.00 | 0.00 | 0.00 | 0.00 |
| NetCommonStockIssuance | 5.81M | 1.56M | 1.50M | 564.00K |
| CommonStockIssuance | 5.81M | 1.56M | 1.50M | 564.00K |
| NetIssuancePaymentsOfDebt | -183.00K | -168.00K | -165.00K | -153.00K |
| NetLongTermDebtIssuance | -183.00K | -168.00K | -165.00K | -153.00K |
| LongTermDebtPayments | -183.00K | -168.00K | -165.00K | -153.00K |
| InvestingCashFlow | 509.00K | 13.88M | 19.91M | 13.41M |
| CashFromDiscontinuedInvestingActivities | 0.00 | 0.00 | ||
| CashFlowFromContinuingInvestingActivities | 509.00K | 13.88M | 19.91M | 13.41M |
| InterestReceivedCFI | 320.00K | 755.00K | 324.00K | 359.00K |
| NetInvestmentPurchaseAndSale | 189.00K | 16.68M | 19.82M | 13.16M |
| SaleOfInvestment | 189.00K | 16.68M | 19.82M | 13.16M |
| PurchaseOfInvestment | 0.00 | |||
| NetBusinessPurchaseAndSale | 0.00 | -3.55M | 0.00 | 0.00 |
| SaleOfBusiness | 0.00 | 0.00 | ||
| PurchaseOfBusiness | 0.00 | -3.55M | 0.00 | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -202.00K | 0.00 |
| PurchaseOfIntangibles | 0.00 | 0.00 | -202.00K | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | -3.00K | -26.00K | -115.00K |
| PurchaseOfPPE | 0.00 | -3.00K | -26.00K | -115.00K |
| OperatingCashFlow | -14.37M | -19.93M | -16.73M | -15.25M |
| CashFromDiscontinuedOperatingActivities | 0.00 | 0.00 | -374.00K | |
| CashFlowFromContinuingOperatingActivities | -14.37M | -19.93M | -16.73M | -14.88M |
| ChangeInWorkingCapital | -4.33M | 274.00K | 3.25M | 744.00K |
| ChangeInOtherWorkingCapital | -162.00K | 11.00K | 27.00K | |
| ChangeInOtherCurrentAssets | 96.00K | 178.00K | 313.00K | -316.00K |
| ChangeInPayablesAndAccruedExpense | -4.43M | 258.00K | 2.93M | 1.03M |
| ChangeInPayable | -4.43M | 258.00K | 2.93M | 1.03M |
| ChangeInAccountPayable | -2.08M | 1.33M | 799.00K | 399.00K |
| ChangeInReceivables | 313.00K | -316.00K | ||
| ChangesInAccountReceivables | 313.00K | -316.00K | ||
| OtherNonCashItems | -3.73M | -2.29M | -843.00K | -108.00K |
| StockBasedCompensation | 582.00K | 1.88M | 2.41M | 2.08M |
| AssetImpairmentCharge | 202.00K | 0.00 | 0.00 | |
| DepreciationAmortizationDepletion | 186.00K | 197.00K | 201.00K | 231.00K |
| DepreciationAndAmortization | 186.00K | 197.00K | 201.00K | 231.00K |
| Depreciation | 186.00K | 197.00K | 201.00K | 231.00K |
| NetIncomeFromContinuingOperations | -7.28M | -19.98M | -21.76M | -17.83M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for PPBT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|